Copyright Reports & Markets. All rights reserved.

Global and United States Recombinant Therapeutic Antibodies and Proteins Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Plasma Protein
    • 1.2.3 Fusion Proteins
    • 1.2.4 Monoclonal Antibodies
    • 1.2.5 Hormones
    • 1.2.6 Enzyme
    • 1.2.7 Coagulation Factors
    • 1.2.8 Others
  • 1.3 Market by Application
    • 1.3.1 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2020 VS 2026
    • 1.3.2 Oncology
    • 1.3.3 Hematology
    • 1.3.4 Immunology
    • 1.3.5 Endocrinology
    • 1.3.6 Infectious Disease
    • 1.3.7 Cardiovascular Disease
    • 1.3.8 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Perspective (2015-2026)
  • 2.2 Global Recombinant Therapeutic Antibodies and Proteins Growth Trends by Regions
    • 2.2.1 Recombinant Therapeutic Antibodies and Proteins Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Recombinant Therapeutic Antibodies and Proteins Historic Market Share by Regions (2015-2020)
    • 2.2.3 Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Market Size
    • 3.1.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue (2015-2020)
    • 3.1.2 Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Players (2015-2020)
  • 3.2 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Recombinant Therapeutic Antibodies and Proteins Revenue
  • 3.4 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio
    • 3.4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Recombinant Therapeutic Antibodies and Proteins Revenue in 2019
  • 3.5 Key Players Recombinant Therapeutic Antibodies and Proteins Area Served
  • 3.6 Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
  • 3.7 Date of Enter into Recombinant Therapeutic Antibodies and Proteins Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Type (2015-2026)

  • 4.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Type (2015-2020)
  • 4.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2021-2026)

5 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Application (2015-2026)

  • 5.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Application (2015-2020)
  • 5.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2026)
  • 6.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
  • 6.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
  • 6.4 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2026)
  • 7.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
  • 7.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
  • 7.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2026)
  • 8.2 China Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
  • 8.3 China Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
  • 8.4 China Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2026)
  • 9.2 Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
  • 9.3 Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
  • 9.4 Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2026)
  • 10.2 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Abbott
    • 11.1.1 Abbott Company Details
    • 11.1.2 Abbott Business Overview
    • 11.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.1.4 Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020))
    • 11.1.5 Abbott Recent Development
  • 11.2 Amgen
    • 11.2.1 Amgen Company Details
    • 11.2.2 Amgen Business Overview
    • 11.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.2.4 Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.2.5 Amgen Recent Development
  • 11.3 Biogen
    • 11.3.1 Biogen Company Details
    • 11.3.2 Biogen Business Overview
    • 11.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.3.4 Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.3.5 Biogen Recent Development
  • 11.4 Eli Lilly
    • 11.4.1 Eli Lilly Company Details
    • 11.4.2 Eli Lilly Business Overview
    • 11.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.4.4 Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.4.5 Eli Lilly Recent Development
  • 11.5 Roche
    • 11.5.1 Roche Company Details
    • 11.5.2 Roche Business Overview
    • 11.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.5.4 Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.5.5 Roche Recent Development
  • 11.6 Johnson and Johnson
    • 11.6.1 Johnson and Johnson Company Details
    • 11.6.2 Johnson and Johnson Business Overview
    • 11.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.6.4 Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.6.5 Johnson and Johnson Recent Development
  • 11.7 Merck
    • 11.7.1 Merck Company Details
    • 11.7.2 Merck Business Overview
    • 11.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.7.4 Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.7.5 Merck Recent Development
  • 11.8 Novo Nordisk
    • 11.8.1 Novo Nordisk Company Details
    • 11.8.2 Novo Nordisk Business Overview
    • 11.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.8.4 Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.8.5 Novo Nordisk Recent Development
  • 11.9 Pfizer
    • 11.9.1 Pfizer Company Details
    • 11.9.2 Pfizer Business Overview
    • 11.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.9.4 Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.9.5 Pfizer Recent Development
  • 11.10 Sanofi
    • 11.10.1 Sanofi Company Details
    • 11.10.2 Sanofi Business Overview
    • 11.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Introduction
    • 11.10.4 Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
    • 11.10.5 Sanofi Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Recombinant Therapeutic Antibodies and Proteins Scope and Market Size
    Recombinant Therapeutic Antibodies and Proteins market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Therapeutic Antibodies and Proteins market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Plasma Protein
    Fusion Proteins
    Monoclonal Antibodies
    Hormones
    Enzyme
    Coagulation Factors
    Others

    Market segment by Application, split into
    Oncology
    Hematology
    Immunology
    Endocrinology
    Infectious Disease
    Cardiovascular Disease
    Others

    Based on regional and country-level analysis, the Recombinant Therapeutic Antibodies and Proteins market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Recombinant Therapeutic Antibodies and Proteins market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Abbott
    Amgen
    Biogen
    Eli Lilly
    Roche
    Johnson and Johnson
    Merck
    Novo Nordisk
    Pfizer
    Sanofi

    Buy now